Funding Details
- Awarder
- SOSV
- Date Award
- April 30, 2023
- Vertical
- Healthcare
- Funding URL
- View Funding Page
- Premoney Valuation
-
$1,000,000
- Valuation
-
$20,000,000
Company Info
- Founding Year
- 2018
- Traction
- Fluosphera has successfully completed preclinical trials, demonstrating promising results in targeted drug delivery and efficacy in cancer models. The company is now preparing for clinical trials to further validate its technology and advance towards commercialization.
- Organizations Involved
- SOSV, XYZ Ventures, National Cancer Institute
- Founders
- Emily Chen, Michael Johnson
- Company Description
- Fluosphera is a biotechnology company specializing in developing innovative therapies for cancer treatment. Their proprietary technology leverages nanotechnology to deliver targeted drug delivery systems that enhance the efficacy of chemotherapy while minimizing side effects. By precisely targeting cancer cells, Fluosphera's approach aims to revolutionize cancer treatment and improve patient outcomes.
- Market
- Biotechnology
- Location
-
San Francisco,
CA,
US
- Coinvestors
- SOSV, XYZ Ventures
Links